Applications
Cell Therapy Manufacturing
Proteios is developing a fully-automated, closed system for the end-to-end manufacturing of autologous and allogeneic cell therapies.
Incorporating a modular design, the cGMP device expands on the preclinical research cell isolation device by adding cell activation/transduction, cell expansion, and therapy formulation modules of various cell capacities.
Additional modules will be provided in the future as the industry incorporates new technologies.
The system will support 2-week and 2-day (i.e., in vivo cell expansion) protocols.
Cell Isolation
Proteios is developing a fully-automated, closed system for the multidimensional isolation of intact immune cells.
Multiple modules can be daisy-chained together to create custom cell processing workflows. Multidimensional isolation allows for the enrichment/depletion of complex cell subtypes that are critical for cell therapy formulations.
Cells isolated in a single dimension (e.g., CD8+ T cells) require less than 30 minutes, while cells isolated in two dimensions (e.g., CD8+ | CD62L+ T cells) require less than 60 minutes. Single-use cartridges of various cell capacities will be available for 20 of the most common immune cell subtypes.
Proteios most recently released its research-scale recombinant protein purification kits.
Proteios Protein Purification kits are based on a proprietary affinity tag- Car9 and a silica-based resin.
The kits provide a viable alternative to His tag technology, which fails with about 20 percent of proteins.
The protein purification kits have the potential to significantly decrease user risk, and improve purification results.